Dianthus Therapeutics Ownership & Insider Activity

Dianthus Therapeutics Inc

DNTHNASDAQ

$84.96

1.952.35%

Last update: Nov 6, 12:00 PM

Earnings: Q3 2026 Earnings were released on Wed Nov 4th, after the market close

Dianthus Therapeutics Ownership & Insider Activity - Benzinga

Dianthus Therapeutics (DNTH) institutional and insider ownership, recent insider transactions and ownership breakdown.

Insiders own 0.2% of shares outstanding. Institutional investors hold 83.4%.

Shares Outstanding

56.313M

Shares Float

49.135M

Insider Shares Owned

84.292K

Insider % Owned

0.2%

Institutional Shares Held

46.667M

Institutional % Held

83.4%

Ownership Breakdown

Net Insider Activity by Month

Date	Insider	Title	Type	Shares	Price	Value
Sep 17, 2026	Edward Carr	CHIEF ACCOUNTING OFFICER	SELL-OPTIONS	—	$59.63	$1.7M
Sep 1, 2026	Simrat Randhawa	EVP, HEAD R&D	SELL-OPTIONS	—	$63.52	$2.0M
Aug 19, 2026	Simon Read	—	SELL-OPTIONS	—	$67.95	$276K
Aug 10, 2026	Anne McGeorge	—	SELL-OPTIONS	—	$60.76	$748K
Aug 10, 2026	Simon Read	—	SELL-OPTIONS	—	$63.96	$253K
Aug 7, 2026	Adam Veness	SVP, GENERAL COUNSEL AND SEC.	SELL-OPTIONS	—	$64.16	$1.9M
Aug 7, 2026	Marino Garcia	CEO AND PRESIDENT	SELL-OPTIONS	—	$58.27	$16.5M
Jul 9, 2026	Ryan Savitz	EVP, CFO & CBO	SELL-OPTIONS	—	$61.40	$2.5M
Jun 17, 2026	Adam Veness	SVP, GENERAL COUNSEL AND SEC.	SELL-OPTIONS	—	$49.34	$1.9M
Jun 1, 2026	Simrat Randhawa	EVP, HEAD R&D	SELL-OPTIONS	—	$54.74	$1.9M
May 8, 2026	Paula Soteropoulos	—	SELL-OPTIONS	—	$46.95	$46K